Physician profile
Tom Chiang
NPI 1346345758
$45,900.58
in general payments reported to CMS, 2019-2025
12 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $2,798 · 2021: $4,007 · 2022: $13K · 2023: $5,076 · 2024: $6,071 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $1,764 · Travel and Lodging: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,000.00 |
| Food and Beverage | $1,764.16 |
| Travel and Lodging | $1,316.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,840.65 | 2021-2025 | Dalvance, Teflaro |
| Shionogi INC | $9,057.18 | 2021-2025 | Fetroja |
| Allergan, INC. | $4,666.41 | 2019-2020 | |
| Janssen Biotech, INC. | $119.08 | 2019-2020 | |
| Melinta Therapeutics, LLC | $49.83 | 2025 | Rezzayo, Kimyrsa, Orbactiv |
| Sobi, INC | $38.16 | 2019 | |
| Boston Scientific Corporation | $34.01 | 2023 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Smith+Nephew, INC. | $26.42 | 2020 | |
| Merck Sharp & Dohme LLC | $23.69 | 2023 | Dificid, Recarbrio, Zerbaxa |
| Kci USA, INC. | $18.09 | 2020 | |
| Gilead Sciences, INC. | $13.68 | 2022 | |
| Dexcom, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Chiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.